Andrew Cooper
Stock Analyst at Raymond James
(2.42)
# 2,345
Out of 4,757 analysts
132
Total ratings
42.74%
Success rate
-0.37%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Reiterates: Outperform | $27 → $19 | $10.34 | +83.75% | 4 | Feb 25, 2025 | |
| GH Guardant Health | Reiterates: Outperform | $39 → $59 | $42.66 | +38.30% | 3 | Feb 21, 2025 | |
| AVTR Avantor | Reiterates: Outperform | $26 → $24 | $15.75 | +52.38% | 14 | Feb 10, 2025 | |
| HAE Haemonetics | Reiterates: Strong Buy | $120 → $115 | $67.16 | +71.23% | 8 | Feb 7, 2025 | |
| HOLX Hologic | Reiterates: Outperform | $95 → $90 | $62.08 | +44.97% | 11 | Feb 6, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $650 → $667 | $524.19 | +27.24% | 6 | Feb 3, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $140 → $145 | $111.73 | +29.78% | 7 | Feb 3, 2025 | |
| DHR Danaher | Downgrades: Market Perform | n/a | $210.56 | - | 8 | Feb 3, 2025 | |
| EXAS Exact Sciences | Reiterates: Market Perform | n/a | $47.63 | - | 8 | Sep 26, 2024 | |
| CDNA CareDx | Downgrades: Market Perform | n/a | $20.42 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $147.92 | -42.54% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $39.67 | +91.58% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.47 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $40.94 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.15 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $32.96 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $16.65 | +170.27% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.25 | - | 5 | Sep 22, 2021 |
Myriad Genetics
Feb 25, 2025
Reiterates: Outperform
Price Target: $27 → $19
Current: $10.34
Upside: +83.75%
Guardant Health
Feb 21, 2025
Reiterates: Outperform
Price Target: $39 → $59
Current: $42.66
Upside: +38.30%
Avantor
Feb 10, 2025
Reiterates: Outperform
Price Target: $26 → $24
Current: $15.75
Upside: +52.38%
Haemonetics
Feb 7, 2025
Reiterates: Strong Buy
Price Target: $120 → $115
Current: $67.16
Upside: +71.23%
Hologic
Feb 6, 2025
Reiterates: Outperform
Price Target: $95 → $90
Current: $62.08
Upside: +44.97%
Thermo Fisher Scientific
Feb 3, 2025
Reiterates: Outperform
Price Target: $650 → $667
Current: $524.19
Upside: +27.24%
Revvity
Feb 3, 2025
Reiterates: Outperform
Price Target: $140 → $145
Current: $111.73
Upside: +29.78%
Danaher
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $210.56
Upside: -
Exact Sciences
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $47.63
Upside: -
CareDx
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $20.42
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $147.92
Upside: -42.54%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $39.67
Upside: +91.58%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.47
Upside: -
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $40.94
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.15
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $32.96
Upside: -
Nov 18, 2022
Initiates: Outperform
Price Target: $45
Current: $16.65
Upside: +170.27%
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.25
Upside: -